Transdentinal cytotoxicity of carbodiimide (EDC) and glutaraldehyde on odontoblast-like cells.

OBJECTIVE: To evaluate the transdentinal cytotoxicity of three different concentrations of carbodiimide (EDC) or 5% glutaraldehyde (GA) on MDPC-23 cells. METHODS: Seventy 0.4-mm-thick dentin disks obtained from human molars were adapted to artificial pulp chambers. MDPC-23 cells were seeded on the pulpal surface of the disks. After 48 hours, the occlusal dentin was acid-etched and treated for 60 seconds with one of the following solutions (n=10): no treatment (negative control); 0.1 M, 0.3 M, or 0.5 M EDC; 5% GA; Sorensen buffer; or 29% hydrogen peroxide (positive control). Cell viability and morphology were assessed by methyltetrazolium assay and scanning electron microscopy (SEM), respectively. The eluates were collected after the treatments and applied on MDPC-23 seeded in a 24-well plate to analyze cell death, total protein (TP), and collagen production. The last two tests were performed 24 hours and seven days after the challenge. Data were analyzed by Kruskal-Wallis and Mann-Whitney tests (p<0.05). RESULTS: EDC at all test concentrations did not reduce cell viability, while 5% GA did increase cell metabolism. Cell death by necrosis was not elicited by EDC or 5% GA. At the 24-hour period, 0.3 M and 0.5 M EDC reduced TP production by 18% and 36.8%, respectively. At seven days, increased TP production was observed in all groups. Collagen production at the 24-hour period was reduced when 0.5 M EDC was used. After seven days, no difference was observed among the groups. SEM showed no alteration in cell morphology or number, except in the hydrogen peroxide group. CONCLUSIONS: Treatment of acid-etched dentin with EDC or GA did not cause transdentinal cytotoxic effects on odontoblast-like cells.

Cytotoxic evaluation of biomechanically improved crosslinked ovine collagen on human dermal fibroblasts.

Earlier studies in our laboratory demonstrated that collagen extracted from ovine tendon is biocompatible towards human dermal fibroblast. To be able to use this collagen as a scaffold in skin tissue engineering, a mechanically stronger scaffold is required that can withstand manipulation before transplantation. This study was conducted to improve the mechanical strength of this collagen sponge using chemical crosslinkers, and evaluate their effect on physical, chemical and biocompatible properties. Collagen sponge was crosslinked with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and glutaraldehyde (GA). Tensile test, FTIR study and mercury porosimetry were used to evaluate mechanical properties, chemical property and porosity, respectively. MTT assay was performed to evaluate the cytotoxic effect of crosslinked collagen sponge on human dermal fibroblasts. The FTIR study confirmed the successful crosslinking of collagen sponge. Crosslinking with EDC and GA significantly increased the mechanical strength of collagen sponge, with GA being more superior. Crosslinking of collagen sponge significantly reduced the porosity and the effect was predominant in GA-crosslinked collagen sponge. The GA-crosslinked collagen showed significantly lower, 60% cell viability towards human dermal fibroblasts compared to that of EDC-crosslinked collagen, 80% and non-crosslinked collagen, 100%. Although the mechanical strength was better when using GA but the more toxic effect on dermal fibroblast makes EDC a more suitable crosslinker for future skin tissue engineering.

Comparative dermal toxicity of dicyclohexylcarbodiimide and diisopropylcarbodiimide in rodents.

Dicyclohexylcarbodiimide (DCC) and Diisopropylcarbodiimide (DIC) are two representative chemicals in the carbodiimide class of chemicals used in industry as stabilizing agents. There is a potential of dermal exposure to these agents in chemical, pharmaceutical and recombinant DNA industries. The National Toxicology Program conducted a number of animal studies to characterize toxicity and carcinogenicity of DIC and DCC. Dermal administration of DCC and DIC in F344/N rats and B6C3F1 mice for 90-days induced skin irritation at the site of application in a dose-dependent manner. Microscopically, dose-dependent increases in epidermal hyperplasia and chronic inflammation were observed. We further evaluated the effects of dermal exposure of DCC and DIC in p53 haploinsufficient and Tg.AC mouse models. Results revealed the skin as the primary target of DCC and DIC exposure as indicated by dose - dependent skin lesions (hyperplasia, inflammation and necrosis). DCC induced squamous cell papillomas in Tg.AC mice but did not induce any neoplastic lesions in p53 haploinsufficient mice. Dermal application of DIC did not induce any neoplastic lesions in Tg.AC mice and p53 haploinsufficient mice. Based on these studies, it was predicted that DIC would be negative and DCC positive for carcinogenic activity in the traditional two-year bioassay. In the subsequent studies, the carcinogenic potential of DIC only in F344 rats and B6C3F1 mice in a traditional 2-year chronic carcinogenicity bioassay was evaluated by the dermal route. Findings revealed the skin as the major target organ of toxicity in both sexes in rats and in male mice. There were no neoplastic lesions observed in rats or mice with the administration of DIC. In rats, there were clinical signs of toxicity in the highest dose-group which included ataxia, excitability, impaired gait, low muscle tone, abnormal breathing, lethargy, and seizures. This was accompanied by non-neoplastic lesions in the brain and lung only at the highest dose level. In conclusion, both DIC and DCC are dermal toxicants. DIC did not have any carcinogenic activity in transgenic mouse models or in the traditional NTP two-year carcinogenicity studies in F344 rats and B6C3F1 mice. DCC was positive in the Tg.AC mouse model and likely to be carcinogenic in the 2-year bioassay as well.

Synthesis and characterization of gelatin nanoparticles using CDI/NHS as a non-toxic cross-linking system.

Gelatin nanoparticles, cross-linked by a mixture of a water soluble carbodiimide (CDI) and N-hydroxysuccinimide (NHS) as a non-toxic cross-linking system, was prepared. The conventional two step desolvation method with acetone as the non-solvent was used. The mean size and size distribution as well as the morphology of the formed nanoparticles were evaluated and compared with those of nanoparticles cross-linked by glutaraldehyde (GA) as the most commonly used cross-linking agent. Furthermore, intrinsic viscosities of the nanoparticles cross-linked by CDI/NHS and GA were measured and compared under various conditions. The results showed the formation of smoother and more homogeneous nanoparticles with smaller size when CDI/NHS used as cross-linking agent under the same synthesis condition. Moreover, nanoparticles encapsulating paracetamol as a model drug were produced by the two different cross-linking agents and were characterized for drug entrapment and loading efficiencies and in vitro drug release. Both drug entrapment and loading efficiencies was higher in the CDI/NHS cross-linked nanoparticles; however, the release kinetics was comparable to that of nanoparticles cross-linked with GA. The differences in the characteristics of CDI/NHS and GA cross-linked nanoparticles were attributed to the different nature of network structures formed by the two cross-linking agents. On the whole, these results suggested that CDI/NHS cross-linked nanoparticles have high potential to be used for drug delivery application in preference to the nanoparticles synthesized by toxic cross-linking agents.

Toxicology and carcinogenesis studies of diisopropylcarbodiimide (Cas No. 693-13-0) in F344/N rats and B6C3F1 mice (dermal studies).

UNLABELLED: Diisopropylcarbodiimide is used as a reagent for peptide syntheses and as a chemical intermediate. The National Cancer Institute nominated diisopropylcarbodiimide for study as a representative chemical in the alkylcarbodiimide class because of its acute toxicity; its use in chemical, pharmaceutical, and recombinant DNA industries; and the absence of data on potential health effects. Male and female F344/N rats and B6C3F1 mice were administered diisopropylcarbodiimide (greater than 99% pure) dermally for 2 weeks, 3 months, or 2 years. Genetic toxicology studies were conducted in Salmonella typhimurium, rat and mouse bone marrow cells, and mouse peripheral blood erythrocytes. 2-WEEK STUDY IN RATS: Groups of five male and five female F344/N rats were dermally administered 0.3 mL ethanol containing 0, 3, 9, 27, or 81 mg diisopropylcarbodiimide or 0.3 mL of the neat chemical containing 242 mg per animal, 5 days a week for 2 weeks. All rats in the 27, 81, and 242 mg groups died before the end of the study. Of the surviving groups, final body weights were similar to those of the vehicle controls. Clinical findings included convulsions/seizures, nasal/eye discharge, tremors, and comatose conditions in 81 and 242 mg rats and lethargy, ataxia, and abnormal breathing in 27 mg rats. The incidences of epidermal hyperplasia at the site of application in 9 and 27 mg males and 27 mg females were significantly greater than those in the vehicle controls; the incidences of hyperkeratosis in 3 and 9 mg males and 9 mg females were also significantly increased. 2-WEEK STUDY IN MICE: Groups of five male and five female B6C3F1 mice were dermally administered 0.1 mL ethanol containing 0, 1, 3, 9, or 27 mg diisopropylcarbodiimide or 0.1 mL of the neat chemical containing 81 mg per animal, 5 days a week for 2 weeks. All 9, 27, and 81 mg mice died before the end of the study. Final body weights of the surviving groups were similar to those of the vehicle controls. Clinical findings in 9, 27, and 81 mg mice included comatose conditions, convulsions/seizures, tremors, abnormal breathing, nasal/eye discharge, lethargy, and irritation at the site of application. Incidences of chronic active inflammation at the site of application in 9 mg males and females were significantly greater than those in the vehicle control groups. 3-MONTH STUDY IN RATS: Groups of 10 male and 10 female core study F344/N rats were dermally administered 0, 10, 20, 40, 80, or 160 mg diisopropylcarbodiimide/kg body weight in ethanol, 5 days per week for 3 months. Groups of 10 male and 10 female clinical pathology rats were administered the same doses for 22 days. All 160 mg/kg core study rats were sacrificed moribund or died within the first week of the study. All 80 mg/kg rats died or were found moribund by day 59. Significant decreases in body weight gain occurred in 40 mg/kg males and females, and a significant decrease in final mean body weight occurred in 40 mg/kg females. Clinical findings in groups administered 40 mg/kg or more generally included irritation of the skin at the site of application, seizures, ataxia, abnormal breathing, ruffled fur, thinness, and lethargy. Significantly increased incidences of skin lesions at the site of application included epidermal hyperplasia in all dosed groups of males (except 160 mg/kg) and 40 mg/kg or greater females, epidermal necrosis in 160 mg/kg males and females, and chronic active inflammation in 80 and 160 mg/kg males and females. Significantly increased incidences of nonneoplastic lesions occurred in the brain, lung, and liver (males only) of rats administered 80 or 160 mg/kg. 3-MONTH STUDY IN MICE Groups of 10 male and 10 female B6C3F1 mice were dermally administered 0, 17.5, 35, 70, 140, or 280 mg/kg diisopropylcarbodiimide in ethanol, 5 days per week for 3 months. All mice in the 280 mg/kg group and nine males and nine females in the 140 mg/kg group died before the end of the study. The final mean body weight gain of 70 mg/kg males was significantly less than that of the vehicle control group. Clinical findings observed in 140 and 280 mg/kg mice included abnormal breathing, ataxia, comatose conditions, convulsions/seizures, irritation at the site of application, lethargy, ruffled fur, and thinness. Significant increases in kidney weights occurred in 17.5 and 35 mg/kg males. Significant decreases in total spermatid heads per testis and average spermatid count occurred in 17.5 mg/kg males. At the site of application, the incidences of epidermal hyperplasia in males and females administered 70 mg/kg or greater, chronic inflammation in 140 and 280 mg/kg males and 70 mg/kg or greater females, and sebaceous gland hyperplasia in 140 mg/kg males were significantly increased. Thymic atrophy was significantly increased in 140 and 280 mg/kg males and females. 2-YEAR STUDY IN RATS: Groups of 50 male and 50 female F344/N rats were dermally administered 0, 10, 20, or 40 mg/kg diisopropylcarbodiimide in anhydrous ethanol 5 days per week for 2 years. Survival of 20 mg/kg males was significantly greater than that of the vehicle controls; survival of all dosed groups of females was similar to that of the vehicle controls. Body weights of 40 mg/kg rats were generally less than those of the vehicle controls after week 13. Clinical findings frequently observed in 40 mg/kg males included ataxia, excitability, impaired gait, low muscle tone, abnormal breathing, lethargy, vocalization, and seizures. Because of severe neurological signs exhibited by the 40 mg/kg males, a neuropathological review of these animals was performed. The principal pathological findings of the brain included neuronal necrosis, hemorrhage, and/or fibrinoid arteriole necrosis. Incidences of hemorrhage in the lung of 40 mg/kg males, chronic lung inflammation in 10 and 20 mg/kg females, and alveolar epithelium hyperplasia in 20 mg/kg females were significantly greater than those of the vehicle controls. At the site of application, the incidences of epidermal hyperplasia in all dosed groups of males and 20 and 40 mg/kg females and chronic inflammation in all dosed groups of males and 40 mg/kg females were significantly increased. There was no increased incidences of neoplasms related to diisopropylcarbodiimide administration. 2-YEAR STUDY IN MICE: Groups of 50 male and 50 female B6C3F1 mice were dermally administered 0, 10, 20, or 40 mg/kg diisopropylcarbodiimide in anhydrous ethanol, 5 days per week for 2 years. Survival of all dosed groups was similar to that of the vehicle control groups. Mean body weights of dosed groups of mice were generally similar to those of the vehicle control groups throughout the study. There were no increased incidences of neoplasms that were attributed to the administration of diisopropylcarbodiimide. Significantly increased incidences of epidermal hyperplasia and focal dermal inflammation of the skin at the site of application occurred in 20 mg/kg male mice. GENETIC TOXICOLOGY: Diisopropylcarbodiimide was not mutagenic in Salmonella typhimurium strains TA97, TA98, TA100, or TA1535 with or without liver S9 activation enzymes. In vivo, the frequency of micronucleated normochromatic erythrocytes was significantly increased in male and female mice after 3 months of dermal exposure to diisopropylcarbodiimide. In addition, significantly elevated frequencies of micronucleated polychromatic erythrocytes (reticulocytes) and micronucleated normochromatic erythrocytes were seen in male mice during a 4-month dermal exposure to diisopropylcarbodiimide. Negative results were obtained, however, in an acute three-injection rat bone marrow micronucleus study. A three-treatment acute micronucleus test in male mice also showed no increase in micronucleated erythrocytes, but results of a single injection micronucleus test in male mice were concluded to be equivocal, due to an increase in micronucleated erythrocytes seen in peripheral blood but not in bone marrow preparations. CONCLUSIONS: Under the conditions of these 2-year dermal studies, there was no evidence of carcinogenic activity of diisopropylcarbodiimide in male or female F344/N rats or B6C3F1 mice administered 10, 20, or 40 mg/kg. Clinical and histological signs of neurotoxicity in male rats were associated with diisopropylcarbodiimide administration.

Toxicology study of diispropylcarbodiimide (CAS No. 693-13-0) in genetically modified (FVB Tg.AC Hemizygous) mice and carcinogenicity study of diispropylcarbodiimide in genetically modified [B6.129-Trp53tm1Brd (N5) haploinsufficient] mice (dermal studies).

UNLABELLED: Diisopropylcarbodiimide is used as a reagent for a variety of reactions including peptide syntheses. The National Cancer Institute nominated diisopropylcarbodiimide for study as a representative chemical in the alkylcarbodiimide class because of its acute toxicity, widespread low-level human exposure, and the absence of data on health effects. Female Tg.AC hemizygous or p53 haploinsufficient mice were administered diisopropylcarbodiimide (greater than 99% pure) dermally for 20 or 27 weeks, respectively. 20-WEEK STUDY IN Tg.AC HEMIZYGOUS MICE: Groups of 10 female Tg.AC hemizygous mice received dermal applications of 0, 4.38, 8.75, 17.5, 35, or 70 mg diisopropylcarbodiimide/kg body weight in ethanol, 5 days a week for 20 weeks. Twelve animals died or were sacrificed moribund prior to the end of the study; two each from vehicle controls, 4.38, 8.75, and 17.5 mg/kg groups, and four from the 35 mg/kg group. Premature deaths were not associated with chemical-related lesions. Odontoma, a common spontaneous finding in Tg.AC hemizygous mice, resulting in jaw malformation, malocclusion, and loss of body condition, occurred in the majority of control, 4.38, 8.75, and 17.5 mg/kg animals that died prematurely. Of the surviving animals, mean body weights were similar to those of vehicle controls. There were no significant changes in organ weights and no treatment-related clinical findings. No neoplasms or nonneoplastic lesions were attributed to administration of diisopropylcarbodiimide. 27-WEEK STUDY IN p53 HAPLOINSUFFICIENT MICE: Groups of 15 female p53 haploinsufficient mice received dermal applications of 0, 4.38, 8.75, 17.5, 35, or 70 mg/kg diisopropylcarbodiimide in ethanol, 5 days a week for 27 weeks. All animals survived to the end of the study. Mean body weights were similar to those of vehicle controls, and there were no treatment-related clinical findings. At necropsy there were no treatment-related gross lesions. Microscopically, there was a higher incidence of treatment-related, predominantly minimal epidermal hyperplasia at the site of application in 70 mg/kg mice than in vehicle controls. No neoplasms were attributed to the administration of diisopropylcarbodiimide. CONCLUSIONS: Under the conditions of this 27-week study, there was no evidence of carcinogenic activity of diisopropylcarbodiimide in female p53 haploinsufficient mice administered 4.38, 8.75, 17.5, 35, or 70 mg/kg in ethanol. There were no treatment-related neoplasms or nonneoplastic lesions in female Tg.AC hemizygous mice administered 4.38, 8.75, 17.5, 35, or 70 mg/kg in ethanol for 20 weeks. Synonyms: 1,3-Diisopropylcarbodiimide; N,N'-diisopropylcarbodiimide; N,N'-methanetetraylbis (2-propanamine).

Induction of micronucleated erythrocytes in rodents by diisopropylcarbodiimide and dicyclohexylcarbodiimide: dependence on exposure protocol.

The induction of micronucleated erythrocytes by diisopropylcarbodiimide (DIC) and dicyclohexylcarbodiimide (DCC) was investigated as part of a U.S. National Toxicology Program (NTP) evaluation of the subchronic toxicity of these chemicals. Analysis of peripheral blood smears from male and female B6C3F1 mice exposed to 17.5-140.0 mg DIC/kg/day by skin painting for 13 weeks revealed dose-related increases in the frequency of micronucleated normochromatic erythrocytes (MN-NCE) in both sexes. Results of a similar 13-week peripheral blood micronucleus (MN) test with DCC (1.5-12.0 mg/kg/day) were also positive, although the increases in MN-NCE were not as great as those observed with DIC. In contrast to the positive results of the subchronic skin-painting studies in mice, acute bone marrow MN studies with DIC and DCC in male F344 rats, using intraperitoneal (i.p.) injection, yielded negative results. Both the acute and the subchronic exposures included doses that produced clinical signs of toxicity. Acute mouse bone marrow MN tests with DIC administered in single or triple i.p. injection protocols were subsequently conducted to determine if the differing responses between mice and rats were due to species or protocol differences. The results of these acute tests were negative or equivocal. Because the subchronic studies produced positive results, it was hypothesized that these carbodiimides required multiple treatments over an extended period of time to produce an increase in MN-erythrocytes. To confirm the original response, a second dermal subchronic study was conducted with DIC; the protocol was modified to include sequential blood samplings to permit monitoring MN frequencies over time. The data demonstrated a small but consistent induction of micronucleated erythrocytes in mice treated with DIC by skin painting.

Contact hypersensitivity to dicyclohexylcarbodiimide and diisopropylcarbodiimide in female B6C3F1 mice.

Dicyclohexylcarbodiimide (DCC) and diisopropylcarbodiimide (DIC) are two commonly used coupling reagents in protein synthesis resulting in exposure of individuals in chemical and pharmaceutical industries as well as research laboratories involved in protein synthesis and recombinant DNA techniques. The objectives of these studies were to determine the irritation and sensitizing potential of these two compounds when applied topically to B6C3F1 mice. Sensitization potential was assessed by the Mouse Ear Swelling Test (MEST) and the murine Local Lymph Node Assay (LLNA). Concentrations used in the contact hypersensitivity assays were determined by primary irritancy studies. DCC and DIC were identified as both irritants and contact sensitizers with the MEST being a more sensitive indicator of sensitization potential. The MEST identified DCC as a sensitizer at concentrations as low as 0.006% (w/v) 24 hr and 48 hr post challenge and DIC at 0.3% (w/v) and 1.5% (w/v) 24 and 48 hr post challenge, respectively. In the LLNA, the lowest concentrations yielding a significant response were 0.06% (w/v) for DCC and 10% (w/v) for DIC.

Analytical, toxicological and immunological consequences of the use of N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide as coupling reagent for the preparation of meningococcal group C polysaccharide-tetanus toxoid conjugate as vaccine for human use.

For the preparation of meningococcal group C polysaccharide-tetanus toxoid conjugate the reactive reagent N-ethyl-N'-(dimethylaminopropyl) carbodiimide is used. The application of this reagent results in a number of stable linkages (viz. "peptide" linkages between the polysaccharide and tetanus toxoid, intrachain ester linkages in the polysaccharide component and binding of the N-acylurea derivative of the reagent) and less stable ones (viz. anhydride linkages). As a consequence of the reaction, the reagent is converted to a non-reactive urea derivative. The toxic properties of the reagent and of the converted reagent were studied. These properties do not contraindicate the use of the coupling reagent for the preparation of vaccines for human use. In addition analytical methods have been developed for the quantitative evaluation of the coupling reagent, the reaction products and for the N-acylurea derivative of the reagent and of the residual reactivity of conjugates for primary aminogroups. Although no test was performed for the assay of ester linkages in the polysaccharide component of the conjugate, evidence is presented that such linkages may be present. The results of the test for residual reactivity indicated a spontaneous rearrangement of linkages after the preparation of the conjugate. In addition the influence of the ratio of coupling reagent-to-polysaccharide and tetanus toxoid on antigenic and immunogenic activities of the conjugate was studied. An increase of the ratio resulted in a decrease of the antigenic activity of the polysaccharide component but in an increase of its immunogenic activity as to the induction of IgG antibodies to the polysaccharide. The immunogenic activity of the polysaccharide component correlated rather well with the antigenic activity measured in heterologous enzyme-linked immunosorbent assay using antibodies to both components.